Clomisign 100 mg (Clomiphene)

What is Clomisign?

Clomisign belongs to the class of non‑steroidal SERMs and contains clomiphene citrate as the active ingredient. It works by blocking estrogen receptors in the hypothalamus, which stimulates the pituitary gland to release more follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). The resulting hormonal rise promotes the development of multiple ovarian follicles and triggers ovulation. The drug is taken orally for five days early in the menstrual cycle and is often the first‑line option for women with polycystic ovary syndrome or unexplained anovulation.

Uses and Benefits

Clomisign is indicated for women who do not ovulate regularly, including those with polycystic ovary syndrome (PCOS) or idiopathic infertility. By inducing ovulation, the medication increases the probability of natural conception without the need for invasive procedures. It can be combined with timed intercourse or intrauterine insemination (IUI) to further improve pregnancy rates. Compared with injectable gonadotropins, Clomisign offers a cost‑effective oral alternative and has a well‑characterized safety profile when monitored by a qualified health professional. Clinical studies report ovulation rates of 70–80 % and pregnancy rates of 30–40 % after six treatment cycles, figures that align with guidance from the NIH.

How It Works

The active ingredient, clomiphene citrate, acts as a partial agonist in the hypothalamus, reducing negative feedback on estrogen receptors. This leads to an increase in circulating FSH and LH, which stimulate follicular growth in the ovary. When sufficient follicular development occurs, a natural LH surge induces ovulation. Peak plasma concentrations are reached within 6–8 hours after ingestion, and the drug’s half‑life is approximately six days, allowing once‑daily dosing during the treatment window.

Dosage Guidelines

Clomisign is typically administered as 100 mg once daily for five consecutive days, beginning on day–3–5 of the menstrual cycle. If ovulation does not occur, the physician may consider increasing the dose to 150 mg or 200 mg in subsequent cycles, but dose escalation should only be performed under medical supervision. The maximum daily dose is 200 mg, and treatment should not exceed six cycles due to the risk of ovarian hyperstimulation. Prior to initiation, baseline hormone panels and pelvic ultrasound are recommended to assess ovarian reserve and rule out contraindications.

Side Effects

Most patients experience mild, transient side effects such as hot flashes, abdominal discomfort, breast tenderness, and nausea. Less common but clinically important adverse events include visual disturbances, ovarian cysts, and, rarely, thromboembolic phenomena. Patients should discontinue the medication and seek immediate medical attention if they develop severe pelvic pain, shortness of breath, or signs of an allergic reaction such as rash or swelling. According to MedlinePlus (MedlinePlus), serious complications are uncommon when the drug is used at recommended doses and under clinical monitoring.

Warnings and Precautions

Clomisign is contraindicated in pregnant or lactating women and in individuals with known hypersensitivity to clomiphene or any excipients. Caution is advised in patients with liver disease, unexplained vaginal bleeding, or ovarian cysts unrelated to PCOS. A thorough evaluation for endometrial hyperplasia or carcinoma is recommended before starting therapy, as prolonged estrogenic activity may increase risk. Concomitant use with other ovulation‑inducing agents should be avoided unless directed by a fertility specialist. For detailed safety data, refer to the FDA label FDA and the NIH clinical guidelines NIH.

Frequently Asked Questions

Q1: How soon after starting Clomisign can I expect ovulation?

A: Ovulation typically occurs 6–10 days after the final dose, though individual timing varies. Ultrasound monitoring can confirm follicular readiness.

Q2: Can Clomisign be used for male infertility?

A: No, Clomisign is approved only for female infertility. Its use in men is not supported by clinical evidence.

Q3: Is it safe for women with PCOS?

A: Yes, Clomisign is commonly prescribed for PCOS‑related ovulatory dysfunction, but dosing may need adjustment and close monitoring is recommended.

Q4: Does the medication increase the chance of multiple pregnancies?

A: Yes, by stimulating multiple follicles, the risk of twins or higher‑order multiples rises, especially at higher doses.

Q5: How should Clomisign tablets be stored?

A: Store at room temperature, away from moisture and heat, and keep the strip sealed until use.

Related Products

• Tretoin 0.1% Gel (Tretinoin)
• Tretoin 0.025% Cream (Tretinoin)
• Tretoin 0.05% Cream (Tretinoin)
• Tretinex Cream (Tretinoin)
• Tretoin Cream (Tretinoin)
• Naltrexone 50 mg (Naltrexone)
• Methylprednisolone (Signapred 4 mg)
• Signapred 4 mg (Methylprednisolone)
• Griseofulvin 500 mg (Generic)
• Lamifil 250 Mg (Terbinafine)
• Fungicyte 150 (Fluconazole 150mg)
• Dermozole 500 mg (Griseofulvin)